Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 2/20 | 0.68 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7756931 | 0.88 | TNF (0.64) | MEN1KMT2ALMNATSHRTP53 | |
| SCHEMBL7761087 | 0.87 | GALR3 (0.67) | GALR3NR2F2MEN1KMT2ANPSR1 | |
| SCHEMBL7761652 | 0.87 | TP53 (0.63) | GALR3NR2F2MEN1KMT2ANPSR1 | |
| SCHEMBL6244545 | 0.81 | AGTR1 (0.65) | MEN1KMT2ALMNATBXA2RTP53 | |
| SCHEMBL12771519 | 0.81 | GALR3 (1.00) | GALR3NR2F2MEN1KMT2ANPSR1 | |
| SCHEMBL7259937 | 0.78 | RAB9A (0.74) | GALR3NR2F2MEN1KMT2ANPSR1 | |
| SCHEMBL7756940 | 0.77 | ALOX5AP (0.64) | MEN1KMT2ANPSR1LMNATSHR | |
| SCHEMBL7762123 | 0.77 | HTT (0.59) | MEN1KMT2ANPSR1RAB9ALMNA | |
| SCHEMBL13941731 | 0.76 | NOD1 (0.63) | GALR3NR2F2MEN1KMT2ANPSR1 | |
| SCHEMBL12771528 | 0.75 | LMNA (0.69) | GALR3NR2F2MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441718-B2 | Selective angiotensin II compounds | VICORE PHARMA AB (SE) | 2025-10-14 | — | — | US | disclosed |
| US-20250101010-A1 | SELECTIVE ANGIOTENSIN II COMPOUNDS | VICORE PHARMA AB (SE) | 2025-03-27 | — | — | US | disclosed |
| US-20240262813-A1 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | VICORE PHARMA AB (SE) | 2024-08-08 | — | — | US | disclosed |
| CN-117916229-A | Novel selective angiotensin II compounds | 维科尔药物公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023281271-A1 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | VICORE PHARMA AB (SE) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262813-A1 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | AGTR1, AGTR2, REN | GALR3 116/4885NR2F2 2410/4885MEN1 999/4885 |
| US-20250101010-A1 | SELECTIVE ANGIOTENSIN II COMPOUNDS | AGTR1, AGTR2, REN | GALR3 99/4885NR2F2 2406/4885MEN1 588/4885 |
| US-12441718-B2 | Selective angiotensin II compounds | AGTR1, AGTR2, REN | GALR3 99/4885NR2F2 2406/4885MEN1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.